rs7151526 — SERPINA1

Regulatory variant downstream of SERPINA1 associated with increased susceptibility to ANCA-associated vasculitis (GPA/MPA) and higher mortality in AAV patients

See your personal result for SERPINA1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SERPINA1 and ANCA Vasculitis — A Protease Balance Variant

Alpha-1 antitrypsin (AAT), encoded by SERPINA1, is the body's most abundant serine protease inhibitor and serves as the primary natural inhibitor of Proteinase 3 (PR3)11 primary natural inhibitor of Proteinase 3 (PR3)
PR3 is a neutrophil-derived serine protease that is the main antigenic target of PR3-ANCA antibodies in granulomatosis with polyangiitis (GPA). When AAT function is compromised, unbound PR3 accumulates on neutrophil surfaces and in the circulation, driving autoantibody formation and vascular inflammation. The rs7151526 variant lies approximately 6.7 kilobases downstream of the SERPINA1 coding sequence, in a non-coding regulatory region near the gene's 3' flank. Though not itself a coding change, it has been identified as a risk factor for ANCA-associated vasculitis (AAV)22 ANCA-associated vasculitis (AAV)
AAV encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA — a group of rare but serious autoimmune conditions affecting small blood vessels, with the A allele significantly overrepresented among GPA patients.

The Mechanism

SERPINA1 encodes AAT, whose primary job is to neutralize PR3 released by activated neutrophils during inflammatory episodes. When PR3 is left uninhibited — whether due to reduced AAT levels or impaired AAT function — it can trigger an autoimmune cascade: unbound PR3 on neutrophil surfaces becomes an exposed antigen, stimulating production of anti-PR3 ANCA antibodies. These antibodies then activate more neutrophils in a self-amplifying loop, causing necrotizing inflammation of small vessels — the hallmark of AAV.

The rs7151526 variant is located in a non-coding region (primarily affecting lncRNA transcripts) with "MODIFIER" impact by VEP annotation. Its exact molecular mechanism of action is not fully characterized; however, regulatory variants in the 3' flanking region of genes can affect mRNA stability, expression level, or splicing of nearby transcripts. Research shows that even in patients with normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis33 normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis
Mota et al. found TIC and specific AAT activity significantly decreased despite equivalent protein levels (p=0.001), suggesting that subtle changes in AAT expression or function — potentially mediated by non-coding regulatory variants like rs7151526 — can tip the protease-antiprotease balance toward disease.

The Evidence

A meta-analysis of 18 eligible studies44 meta-analysis of 18 eligible studies
Banerjee et al., International Journal of Rheumatic Diseases, 2022 confirmed rs7151526-A as a significant predisposing allele for GPA (Meta-OR = 2.70, 95% CI 1.51–4.85, p = 0.0008). This finding was consistent across studies and confirms that carrying the A allele approximately doubles to triples the odds of developing GPA compared to CC homozygotes.

The clinical stakes are considerable. A 2024 prospective cohort study of 115 Brazilian AAV patients55 2024 prospective cohort study of 115 Brazilian AAV patients
Giardini et al., Clinics (São Paulo), 2024 — predominantly GPA (65.2%) — found SERPINA1 polymorphisms to be "the most significant factor linked to mortality" in multivariate analysis (HR = 6.2, 95% CI 1.4–27.1, p = 0.015). Carriers of rs7151526 had a mean survival of 57.4 years, compared to 68.0 years in non-carriers — a reduction of more than a decade. A French retrospective cohort of 142 AAV patients66 French retrospective cohort of 142 AAV patients
Deshayes et al., Journal of Rheumatology, 2019 found that patients with deficient AAT alleles had significantly higher rates of intraalveolar hemorrhage (p < 0.01), a severe and potentially fatal pulmonary complication.

Population frequencies confirm this is a predominantly European variant: the A allele occurs at ~4.8% in Europeans, versus ~0.1% in East Asians and ~0.9% in Africans. The overall global minor allele frequency is approximately 3.4% (gnomAD v4). Given the additive genetic architecture and the rarity of AAV itself (~3 per 100,000 per year), the absolute risk increase is modest, but the prognostic impact once disease develops appears substantial.

Practical Actions

Carrying the A allele does not mean you will develop AAV — the condition remains rare even in genetically predisposed individuals, and environmental triggers (infections, silica exposure, drugs) are required. However, awareness of this genetic signal supports a lower threshold for clinical evaluation when relevant symptoms appear. ANCA-associated vasculitis characteristically presents with upper respiratory tract symptoms77 upper respiratory tract symptoms
ENT symptoms including chronic sinusitis, nosebleeds, saddle-nose deformity in GPA; subglottic stenosis, lower respiratory disease (cough, hemoptysis), kidney involvement (hematuria, proteinuria, rising creatinine), and systemic features (fatigue, weight loss, fever). Prompt ANCA testing and rheumatology referral at symptom onset significantly improves outcomes.

For those who carry this variant, early disease recognition is the most actionable step. ANCA-associated vasculitis treated in early disease stages — before irreversible organ damage — has substantially better outcomes than disease diagnosed late with severe renal or pulmonary involvement.

Interactions

rs7151526 is distinct from the classical SERPINA1 deficiency alleles (rs28929474, the Z allele E342K, and rs17580, the S allele E264V). The Z allele (rs28929474) is strongly pathogenic for classic AAT deficiency lung and liver disease, and is independently associated with even stronger GPA risk (Meta-OR = 12.60 for the Z allele versus 2.70 for rs7151526 in Banerjee 2022). The related SNP rs28929454 (also studied in the Giardini 2024 mortality cohort) showed even more pronounced survival reduction. Individuals carrying rs7151526-A alongside classical deficiency alleles would likely face compounded risk, though direct interaction data is limited.

The mechanism connects rs7151526 to the broader ANCA vasculitis genetic architecture, which includes variants in CTLA4 (rs231775) and other immune regulatory genes identified in the same meta-analysis. PR3-ANCA positive AAV has distinct genetic risks from MPO-ANCA positive disease, and rs7151526's association appears primarily driven by GPA (PR3-ANCA) cases.

Genotype Interpretations

What each possible genotype means for this variant.

CC Non-carrier Normal

No rs7151526 risk allele — typical background risk for ANCA vasculitis

You carry two copies of the common C allele and do not have the rs7151526 risk variant. Your genetic risk for ANCA-associated vasculitis from this locus is at the population baseline. About 93% of people globally share this genotype. ANCA vasculitis can still occur without this variant — other genetic and environmental factors also contribute — but you do not carry this specific susceptibility signal.

AA High Risk

Homozygous risk genotype — substantially elevated ANCA vasculitis susceptibility

rs7151526 lies in a regulatory region approximately 6.7 kb downstream of the SERPINA1 coding sequence. SERPINA1 encodes alpha-1 antitrypsin (AAT), the primary inhibitor of Proteinase 3 (PR3), which is the main autoantigen in PR3-ANCA-positive granulomatosis with polyangiitis (GPA). When AAT function is insufficient, uninhibited PR3 on neutrophil surfaces drives ANCA autoantibody formation and vascular inflammation.

The AA genotype confers the maximum additive genetic risk from this locus. Given the 2024 mortality data (Giardini et al.) showing mean survival of 57.4 vs 68.0 years for SERPINA1 SNP carriers with active AAV, early diagnosis and specialist involvement are particularly important.

AC High Risk

One copy of risk allele — moderately elevated ANCA vasculitis risk

The rs7151526-A allele's association with GPA susceptibility (Meta-OR=2.70 in Banerjee 2022, based on 18 studies) represents the best-replicated genetic evidence for this SNP. The variant is located in a regulatory region downstream of SERPINA1, which encodes alpha-1 antitrypsin — the primary inhibitor of Proteinase 3 (PR3), the main ANCA autoantigen in GPA. Although the exact molecular mechanism is not fully characterized, the association pattern is consistent with reduced AAT regulatory efficiency, allowing increased free PR3 and heightened autoantibody formation risk.

The 2024 mortality study (Giardini et al.) examined SERPINA1 SNP carriers broadly and found reduced survival in established AAV patients, underscoring that if disease develops, genetic background matters prognostically.